help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lippuner, K.
Right arrow Articles by Jaeger, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lippuner, K.
Right arrow Articles by Jaeger, P.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 11 3795-3802
Copyright © 1998 by The Endocrine Society

Original Studies

Effects of Deflazacort Versus Prednisone on Bone Mass, Body Composition, and Lipid Profile: A Randomized, Double Blind Study in Kidney Transplant Patients1

Kurt Lippuner, Jean-Paul Casez, Fritz F. Horber and Philippe Jaeger

Policlinic of Medicine, University Hospital of Berne, 3010 Berne, Switzerland

Address all correspondence and requests for reprints to: Philippe Jaeger, M.D., F.R.C.P., Policlinic of Medicine, University Hospital, 3010 Berne, Switzerland.


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
To compare the effects of deflazacort (DEFLA) vs. prednisone (PRED) on bone mineral density (BMD), body composition, and lipids, 24 patients with end-stage renal disease were randomized in a double blind design and followed 78 weeks after kidney transplantation. BMD and body composition were assessed using dual energy x-ray absorptiometry. Seventeen patients completed the study. Glucocorticosteroid doses, cyclosporine levels, rejection episodes, and drop-out rates were similar in both groups. Lumbar BMD decreased more in PRED than in DEFLA (P < 0.05), the difference being particularly marked after 24 weeks (9.1 ± 1.8% vs. 3.0 ± 2.4%, respectively). Hip BMD decreased from baseline in both groups (P < 0.01), without intergroup differences. Whole body BMD decreased from baseline in PRED (P < 0.001), but not in DEFLA. Lean body mass decreased by approximately 2.5 kg in both groups after 6–12 weeks (P < 0.001), then remained stable. Fat mass increased more (P < 0.01) in PRED than in DEFLA (7.1 ± 1.8 vs. 3.5 ± 1.4 kg). Larger increases in total cholesterol (P < 0.03), low density lipoprotein cholesterol (P < 0.01), lipoprotein B2 (P < 0.03), and triglycerides (P = 0.054) were observed in PRED than in DEFLA.

In conclusion, using DEFLA instead of PRED in kidney transplant patients is associated with decreased loss of total skeleton and lumbar spine BMD, but does not alter bone loss at the upper femur. DEFLA also helps to prevent fat accumulation and worsening of the lipid profile.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
BONE LOSS (1), muscular wasting (2), carbohydrate intolerance (3) and redistribution of total body fat (4) are the price of long term glucocorticotherapy. Recently, we have shown that early after grafting, kidney transplant recipients lose significant amounts of mineral from axial skeleton, with a nadir at 6 months (5) and partial recovery between 6 and 18 months (6) after transplantation. The cumulative dose of prednisone (PRED) was a major determinant of bone loss in these patients. Deflazacort (DEFLA), an oxazoline analog of PRED, has been shown to affect intestinal calcium absorption (7) and urinary excretion of calcium and hydroxyproline (8, 9) much less than the parent substance, at least on a short term basis. Treatment with DEFLA for several months or more also induced less bone loss than other corticosteroids, as assessed by photon absorptiometry (10) or bone histomorphometry (11). However, controlled long term studies using the precise technique of dual energy x-ray absorptiometry (DXA) are lacking to support this concept.

Furthermore, DEFLA has been shown to have fewer side-effects than PRED on glucose and lipid metabolism (12); its use may thus be of interest in transplant recipients, inasmuch as DEFLA appears to have a similar immunosuppressive effect as PRED, e.g. in heart transplant patients (13). However, the effect of DEFLA vs. PRED on body composition, i.e. fat and lean mass in such patients has not been precisely studied to date.

DXA allows accurate and precise determination not only of bone mass, but also of lean and fat mass of the whole body (14); it also appears to be the most sensitive method for the assessment of muscle wasting as well as of fat repartition (15) that contributes to the Cushingoid aspect of steroid-treated patients. We undertook this prospective, randomized, double blind study to compare the effects on bone, body composition and lipids of DEFLA and PRED in patients after kidney transplantation (KTX).


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
Patients

Twenty-four patients with end-stage renal disease (ESRD) who underwent cadaveric KTX were randomized into this double blind study between December 1992 and June 1994. Five patients dropped out within the first 5 months: one patient (A.E., no. 5-202, male, DEFLA) did not want to continue the study for personal reasons, one patient (A.B., no. 4-301, male, DEFLA) died 5 months after KTX from rupture of an aortic aneurysm associated with nocardiosis, another one (F.S., -9–302, male, PRED) died 10 weeks after KTX from multiple organ failure of septic origin. In one patient (V.G., no. 13-206, male, PRED), irreversible graft rejection occurred 9 days after KTX. One patient (E.M., no. 21-107, female, DEFLA) was excluded after 10 weeks because the dose of methylprednisolone administrated iv exceeded the upper limit allowed by the protocol (i.e. 3 g). Thus, there remained 19 patients who were investigated.

ESRD was due to glomerulonephritis (n = 7), analgesic abuse nephropathy (n = 1), reflux nephropathy (n = 1), polycystic kidney disease (n = 8), Fabry’s disease (n = 1), and familial interstitial nephropathy (n = 1). Before KTX patients had been receiving chronic dialysis (hemo-dialysis, n = 16; chronic ambulatory peritoneal dialysis, n = 4) for 33 ± 7 (mean ± SEM) months (range, 8–120 months).

The study had been approved by the ethical committee at the University of Berne School of Medicine, and written informed consent was obtained from all subjects after the nature of the procedures had been fully explained.

Study design

Clinical parameters and renal function were monitored twice a week during the first month, on a weekly basis up to month 3, and every 2 weeks thereafter. Complete laboratory assessment (blood and urine) was performed 1, 4, 6, 12, 24, 36, 52, 64, and 78 weeks after KTX. Bone density and body composition were measured at the same visits, except at weeks 4 and 52.

Immunosuppression and concomitant drug therapy

All patients were treated with glucocorticosteroids and cyclosporin A. Azathioprine was added to the regimen in eight patients; in two of them it was given from time of KTX on, and in six patients it was given later (i.e. 2–12 months after KTX).

Oral glucocorticosteroid therapy was given as tablets of 5 and 1 mg PRED or 6 and 1.2 mg DEFLA, following as closely as possible an ideal schedule depicted in Fig. 1Go. This dose ratio of 1.2:1 had been established in earlier studies (9, 16, 17, 18).



View larger version (19K):
[in this window]
[in a new window]
  		Figure 1. Ideal and actual daily doses of glucocorticosteroids (triangles, ideal; squares, PRED; circles, DEFLA) after kidney transplantation. The DEFLA dose is expressed as a prednisone equivalent dose on the basis of 1.2 mg DEFLA = 1 mg PRED.

 
Acute graft rejection episodes were treated with iv methylprednisolone (500 mg/day) for a maximum of 6 days. Patients who had received more than six boluses of methylprednisolone (i.e. >3 g) were excluded from the study.

Four patients (one PRED and three DEFLA) received phosphate supplementation for symptomatic hypophosphatemia. Hypertension (n = 16) was treated with ß-blockers, calcium channel blockers, and/or angiotensin-converting enzyme inhibitors. Ranitidine was used to prevent peptic ulcer in all patients as long as the daily dose of glucocorticosteroids was above 15 mg prednisone equivalent. One woman (DEFLA) was receiving hormone replacement therapy (HRT; Premarin® 0.625, Wyeth AHP, Schweiz AG, Zug, Switzerland) at the time of enrollment; the treatment was continued throughout the study. Hypercholesterolemia was treated with simvastatin in one patient (DEFLA, treatment started 3 months after KTX) and with fenofibrate in the two patients (one DEFLA and one PRED), who dropped out after 24 weeks.

DXA measurements

DXA (Hologic QDR 1000W) was performed to measure bone mineral density (BMD) at the lumbar spine and proximal femur of the nondominant leg. In addition, whole body was scanned for assessment of total skeletal BMD and body composition (i.e. lean body mass and fat body mass). Precision error in vitro was 0.4% for BMD, based on daily scanning of an anthropometric phantom supplied by the manufacturer. No drift was seen during the period of investigation. Based on repeated measurements performed at our institution, precision error in vivo is 1% or less for BMD at all sites and for body composition.

Blood and urine collection, biochemistry

Fasting plasma concentrations of calcium, phosphorus, creatinine, glucose, glycosylated hemoglobin; serum concentrations of triglycerides, cholesterol [total, low density lipoprotein (LDL), and high density lipoprotein (HDL)], and apolipoproteins A1 and B2; as well as plasma alkaline phosphatase activity were measured using standard techniques in the central laboratory at our institution. Ionized calcium was measured in whole blood using an ion-selective electrode (Ciba-Corning Diagnostics Corp., Medfield, MA). The serum concentration of intact PTH was measured using an immunoradiometric assay (Allegro, Nichols Institute Diagnostics, San Juan Capistrano, CA). Serum concentrations of 25-hydroxyvitamin D and osteocalcin were measured by RIAs (Nichols Institute Diagnostics).

Fasting urine samples (second morning voided urine) were analyzed for calcium and creatinine by autoanalyzer techniques. Urinary deoxypyridinoline was measured by high performance liquid chromatography (19) and expressed as the deoxypyridinoline/creatinine ratio.

Twenty-four-hour urine was collected and analyzed for calcium and creatinine by autoanalyzer techniques. Creatinine clearance was calculated and adjusted for 1.73 m2.

Data analysis

All values are expressed as the mean ± SEM. Changes over time were analyzed with ANOVA for repeated measures with post-hoc t tests using a statistical software package (StatView 4.0 and SuperAnova, Abacus Concepts, Berkeley, CA). Two-way ANOVA was used to judge the time-group interaction. If necessary (as was the case for lumbar BMD), intergroup differences at baseline were corrected using analysis of covariance.

Analysis was performed over 78 weeks for the 17 patients (10 PRED and 7 DEFLA) who completed the study, with additional analysis over 24 weeks for the 19 patients (11 PRED and 8 DEFLA; including the 2 patients who dropped out after 6 months).


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
Baseline characteristics of the patients (12 women and 7 men) are given in Tables 1Go and 2Go. All parameters were similar between groups, with the exception of lumbar BMD, which was significantly lower in the group treated with PRED than in that given DEFLA.


View this table:
[in this window]
[in a new window]
  		Table 1. Bone mineral density, body composition, and parameters of carbohydrate/lipid metabolism at baseline

 

View this table:
[in this window]
[in a new window]
  		Table 2. Bone parameters at baseline and after 24 and 78 weeks

 
Rejection episodes occurred in 5 of the 19 patients followed, 3 of them belonging to PRED and 2 to the DEFLA group. Two of them (males) dropped out after week 24: 1 patient (DEFLA) for ESRD and the other (PRED) for having received more than 6 boluses (3 g) of methylprednisolone. Immunosuppressive therapy, including PRED dose, was similar in both groups; based on the equivalence ratio of PRED:DEFLA = 1: 1.2, the cumulative oral steroid dose was similar in both groups both after 24 weeks (PRED, 66 ± 6 mg/kg prednisone; DEFLA, 80.4 ± 4.8 mg/kg deflazacort; P = NS; 19 patients) and at the end of the study (PRED, 132 ± 14 mg/kg prednisone; DEFLA, 151.2 mg/kg deflazacort; P = NS; 17 patients). Patients had also received similar doses of iv methylprednisolone after 24 weeks (PRED, 35 ± 4 mg/kg; DEFLA, 27 ± 7 mg/kg; P = NS; n = 19) and at the end of the study (PRED, 33 ± 4 mg/kg; DEFLA, 29 ± 6; P = NS; n = 17). Cyclosporine blood trough levels did not differ significantly at any time point between the groups (data not shown). Azathioprine had been given to 5 of 11 patients in the PRED group vs. 3 of 8 patients in the DEFLA group.

The blood ionized calcium concentration at baseline was above the normal range (1.15–1.30 mmol/L) in 8 patients and below the normal range in 2 patients; the mean value was above the upper normal limit. The plasma phosphate concentration was below the normal range (0.74–1.55 mmol/L) in 11 patients and was normal in the remaining patients. The mean value was below the normal range. The intact PTH serum concentration was above the normal range (10–65 pg/mL) in 9 patients and below the normal range in 1 patient; as expected in patients with ESRD, the mean value was above the upper normal limit. The mean daily calcium excretion was below the normal range. No patient had a low serum level of 25-hydroxyvitamin D. Normal values were found for markers of osteoblast activity, i.e. plasma alkaline phosphatase activity and serum osteocalcin concentration. However, mean urinary excretion of deoxypyridinoline, a marker of bone resorption, was slightly above the normal range. Finally, patients had normal serum total and LDL cholesterol, decreased HDL cholesterol and apolipoprotein A1, and slightly elevated triglycerides.

Bone metabolism

Bone density measurements. Figure 2Go depicts BMD changes over time at different skeletal sites for the 17 patients who completed the study.



View larger version (28K):
[in this window]
[in a new window]
  		Figure 2. BMD (left) and body composition (right) changes in patients receiving either PRED (rectangles) or DEFLA (filled circles). Statistics were determined by ANOVA for repeated measurement and post-hoc t tests (°, P < 0.05 vs. baseline; *, P < 0.05 between groups). ANOVA results: spine BMD, changes significant in PRED (P < 0.0001), but not in DEFLA, with significant intergroup difference (P < 0.05); upper femur BMD, changes significant in both groups (P < 0.01), with no significant intergroup difference; whole body BMD, changes significant in PRED (P < 0.001), but not in DEFLA, with no significant intergroup difference; fat body mass, changes significant in both groups (P < 0.001), with significant intergroup difference (P < 0.01); lean body mass, changes significant in both groups (P < 0.001), with no significant intergroup difference; body weight, changes significant in both groups (P < 0.001), with no significant intergroup difference.

 
Lumbar spine. Whereas in the PRED group, BMD significantly decreased over time (P < 0.0001, by one-way ANOVA for repeated measurements), it did not significantly change in the DEFLA group (P = NS). Intergroup differences were significant (P < 0.05) even after correction for baseline intergroup difference using analysis of covariance. At the end of the study, patients treated with PRED had lost 8.0 ± 2.2% of their initial BMD (P < 0.01), whereas patients treated with DEFLA had BMD similar to that measured at baseline (-1.4 ± 3.6%;P = NS vs. baseline).

Upper femur. At the upper femur, a significant decline in BMD from baseline was observed in both groups (P < 0.01, by ANOVA for repeated measurements). There were no significant intergroup differences.

Total skeleton. Whole body BMD significantly decreased from baseline in PRED (P < 0.001, by ANOVA for repeated measurements), but not in DEFLA (P = NS), patients. After 78 weeks, PRED patients had lost 2.3 ± 0.8% of their baseline BMD (P < 0.02), whereas DEFLA patients had no significant bone loss compared with baseline (-0.8 ± 0.1%; P = NS). Intergroup comparison by two-way ANOVA, however, did not reveal significant differences between PRED and DEFLA due to the large SEM combined with the low number of patients per group.

Statistical comparisons including all 19 patients from baseline to week 24 gave similar results and showed significance at all sites measured (data not shown). Excluding the patient receiving HRT did not influence the results.

Biochemical parameters

Table 2Go gives baseline values and changes in the laboratory parameters observed between weeks 1 and 24 as well as week 78.

Creatinine clearance improved slightly to reach a mean value of 62 ± 4 mL/min·1.73 m2 at the end of the study. There was a marginal rise in the blood ionized calcium concentration. Serum phosphate concentrations normalized (1.08 ± 0.04 mmol/L), and the mean serum level of intact PTH decreased to the upper normal range (62 ± 13 pg/mL). Neither plasma alkaline phosphatase activity nor urinary excretion of deoxypyridinoline significantly changed over time, whereas the mean osteocalcin serum concentration increased up to the high normal range (10.1 ± 1.6 ng/mL). The mean daily urinary excretion rate of calcium also returned to the normal range (3.4 ± 0.4 mmol/24 h).

For any of these parameters, no difference was found between the groups. Excluding the patient receiving HRT did not influence the results.

Body composition, and lipid and carbohydrate metabolism

Body composition. Figure 2Go displays changes in body weight, lean body mass, and fat mass.

Body weight varied significantly in both groups (P < 0.001), with an early decrement by approximately 2.5 kg after 6 weeks (P < 0.01). Thereafter, body weight increased up to week 78 in patients taking PRED (+3.8 ± 2 kg; P < 0.05) but only tended to do so in those taking DEFLA (+1.8 ± 1 kg; P = 0.18). Differences between groups did not reach statistical significance.

Lean body mass significantly decreased from baseline (P < 0.001) in both groups, with no significant intergroup difference. There was no correlation between the changes in lean body mass and the changes in urinary creatinine excretion at any time point.

Conversely, fat mass significantly increased in both groups (P < 0.001). However, this increment occurred earlier in the time course and was of greater extent in the PRED compared with the DEFLA group (P < 0.01). At the end of the study, fat mass had increased by 7.1 ± 1.8 kg in the PRED group compared with 3.5 ± 1.4 kg in the DEFLA group.

Lipid and carbohydrate metabolism (Table 1Go and Fig. 3Go). There was no significant difference between the PRED and DEFLA groups at baseline with respect to serum parameters of lipid and carbohydrate metabolism. Serum levels of total, HDL, and LDL cholesterol as well as of lipoproteins A1 and B2 increased significantly (P < 0.001) in both groups. This increase was more marked in the PRED than in the DEFLA group for total cholesterol (P < 0.03), LDL cholesterol (P < 0.01), and lipoprotein B2 (P < 0.03). These results persisted after exclusion of the patient receiving simvastatin (the two patients taking fenofibrate had not completed the study and were therefore excluded from analysis). Serum concentrations of triglycerides tended to increase in the PRED group and decreased slightly in the DEFLA group (P < 0.05). The plasma glucose concentration did not change significantly in either group. However, there was a nonsignificant trend (P = 0.17) for higher blood glucose concentration in the PRED group (6.1 ± 0.6 mmol/L) compared with that in the DEFLA group (5.05 ± 0.22 mmol/L) at month 6. Hemoglobin A1c did not change significantly in either group (data not shown).



View larger version (35K):
[in this window]
[in a new window]
  		Figure 3. Changes in serum lipids after kidney transplantation in patients receiving either PRED (rectangles) or DEFLA (filled circles). Statistics were determined by ANOVA for repeated measurement and post-hoc t tests (°, P <= 0.05 vs. baseline; *, P <= 0.05 between groups). ANOVA results: total cholesterol, LDL cholesterol, and lipoprotein B2, changes significant in both groups (P < 0.001), with intergroup differences (P < 0.03–0.01); HDL cholesterol and lipoprotein A1, changes significant in both groups (P < 0.001), with no significant intergroup difference; triglycerides, changes significant in DEFLA (P < 0.05), but not in PRED (P = 0.07), with intergroup difference (P = 0.054).

 
Excluding the patient receiving HRT did not influence results for body composition or lipids.


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
The present study shows for the first time that using DEFLA instead of PRED in kidney transplant patients helps to prevent bone loss at the lumbar spine and whole body and leads to lower fat accumulation and a lesser impairment of the lipid profile.

An important issue to be addressed when comparing two glucocorticosteroids is their respective potency. Fewer side-effects may be related to less primary activity. The bioequivalence of DEFLA and PRED has been investigated in various situations. In normal subjects (20), 15 mg DEFLA inhibit T cell reactivity to the same extent as 12.5 mg PRED, but for a longer period of time (based on phytohemagglutinin-induced T cell proliferation in vitro).

Based on the results of seven trials of various design, including double blind cross-over studies, paired patient studies, and between-patient studies involving 160 patients, the potency ratio of DEFLA vs. PRED was estimated by Avioli to be 1.28 (16). In fact, the equivalence ratio of DEFLA/PRED may depend on the disease [i.e. 1.2:1 in rheumatoid arthritis (9), juvenile chronic arthritis (17), and nephrotic syndrome (18); 1.4:1 in asthma (21) and polymyalgia rheumatica (22)]. Few data are available for kidney transplantation. In a study comparing DELFA vs. methylprednisolone using a 1.5:1 ratio (which is equivalent to a 1.2:1 DEFLA/PRED ratio), Elli et al. (23) concluded that there was a more potent immunosuppressive activity of DEFLA with a lower ratio of CD4+/CD8+ lymphocytes. Taken together, these data support the 1.2:1 potency ratio used in the present study. Indeed, we did not observe any differences in the glomerular filtration rate or the number of graft rejection episodes between the two groups. The actual glucocorticoid dosage was, in fact, much higher than the preplanned schedule, because physicians adjusted the dose visit after visit according to clinical status and creatinine levels to be on the safe side and to avoid a rejection crisis. Despite this individual dose adjustment, the daily and cumulative doses administered were strictly equivalent in both groups according to the 1.2:1 ratio.

One can argue that the study lacks statistical power to be really conclusive. Due to fewer graft donors than foreseen, the planned sample size of 60 could not be achieved. However, our results for bone density of the PRED group are perfectly consistent with previous studies of kidney transplant patients receiving that drug showing predominant bone loss at lumbar spine and relative bone preservation at limbs (5, 24). Julian et al. (24) found a 6.8% decrease in lumbar BMD 6 months after renal transplantation, with no further loss up to 18 months and a slight increase in the BMD of the radius. In a previous study by our group, patients lost an average of 7% of lumbar BMD and 2% of whole body BMD during the first 5 months after KTX, whereas they did not lose bone mineral at limbs (5). In the present study, lumbar and whole body BMD decreased by 9.1% and 2.3% in PRED-treated patients compared to 3% and 0.8%, respectively, in DEFLA-treated patients. This 6% bone-sparing effect at the lumbar spine would approximately correspond to a reduction by 1.4-fold in the risk of vertebral fractures (25).

A bone-sparing effect of DEFLA at the level of lumbar spine has been described in various clinical situations. In a 1-yr double blind prospective study of patients with the nephrotic syndrome, bone loss induced by PRED at the lumbar spine was 1.9-fold higher (12.5%/yr) than that induced by DEFLA (6.8%) (26). In a randomized double blind prospective study of adult men with newly diagnosed rheumatoid arthritis, patients given DEFLA experienced spinal bone loss at one third the rate of that observed in the subjects receiving PRED at equivalent dosage (27). Another 12-month study of 22 patients with rheumatoid arthritis, asthma, or sarcoidosis revealed a 10%/yr bone loss during DEFLA vs. 21% during PRED treatment (28). Furthermore, in children with juvenile chronic arthritis, spinal bone growth was greater during DEFLA than during PRED treatment (17).

It has been suggested that DEFLA depresses the osteoblast less than PRED, leading to a smaller decrease in serum osteocalcin levels with this drug (29). Surprisingly, in our patients serum osteocalcin levels increased in both groups despite decreasing PTH levels. This finding can be explained by cyclosporin A cotreatment, which is known to increase bone turnover (30). Other researchers have claimed that some of the bone-sparing effect of DEFLA compared to that of PRED could be explained by a less impaired intestinal calcium absorption by the former (31). The fact that 1) serum ionized calcium significantly increased in the DEFLA but not in the PRED group; 2) the mean intact PTH level showed a trend to a more marked reduction in the former (-57%) compared with the latter (21%) group; and 3) calciuria tended to increase more in the DEFLA (+200%) than in the PRED (+95%) group suggests better calcium absorption during DEFLA than during PRED treatment.

The lack of statistical significance could be due to the particular condition of renal transplantation that restores 1{alpha}-hydroxylase activity, leading to increased calcitriol serum levels (not measured in this study) and calcium absorption.

Fat accumulation is a well known side-effect of glucocorticoid therapy as a consequence of peripheral resistance to insulin with decreased glucose tolerance and increased serum levels of triglycerides. Obviously, the increase in fat mass was less marked in our patients treated with DEFLA (+3 kg) than in those treated with prednisone (+7 kg). As a consequence, triglycerides increased less in the DEFLA-treated patients, although fasting blood glucose and hemoglobin A1c levels were similar in the treatment groups. An additional beneficial effect of DEFLA was found for total cholesterol, LDL cholesterol, and lipoprotein B2. In renal transplant patients, Elli et al. (23) also observed lesser weight gain, better glucose tolerance, and lower increase in serum levels of cholesterol and triglycerides with DEFLA than with methylprednisolone. In another study of 31 heart transplant patients randomized to either DEFLA or PRED (at a dose ratio of 1.5:1), lower serum glucose levels were observed after 3 months in the DEFLA group (32).

Lean body mass decreased early after grafting in both groups, probably due to a reduction in the degree of hydration of those patients (33) rather than to decreased muscle mass. This hypothesis is supported by the lack of correlation between changes in lean body mass and those in creatinine excretion.

In conclusion, DEFLA as an alternative to PRED helps to prevent bone loss and fat accumulation after kidney grafting. It may also contribute to the prevention of coronary heart disease by lesser impairment of the lipid profile compared with PRED.


   Acknowledgments
 
We thank Ms. Elisabeth Dijkhuis for her invaluable contribution as the coordinator of the study.


   Footnotes
 
1 This work was supported by a grant from Hoechst Marion Roussel, Inc., CH-8048 Zürich, Switzerland. Back

Received April 13, 1998.

Revised July 20, 1998.

Accepted July 28, 1998.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Sambrook PN, Jones G. 1995 Corticosteroid Osteoporosis. Br J Rheum. 34:8–12.[Abstract/Free Full Text]
  2. Harman JB. 1959 Muscular wasting and corticosteroids therapy. Lancet. 1:887.
  3. Olefsky JM, Kimmerling G. 1976 Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci. 271:202–210.[Medline]
  4. Steiger U, Lippuner K, Jensen EX, Montandon A, Jaeger PH, Horber FF. 1995 Body composition and fuel metabolism after kidney grafting. Eur J Clin Invest. 25:809–816.[Medline]
  5. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger Ph. 1994 Changes in bone mass early after kidney transplantation. J Bone Miner Res. 9:1–9.[Medline]
  6. Horber FF, Lippuner K, Casez JP, Montandon A, Jaeger Ph. 1993 Long-term effects of renal transplantation on bone compartments: a prospective study [Abstract]. J Am Soc Nephrol. 4:637.
  7. Caniggia A, Marchetti M, Gennari C, Vattimo A, Nicholis FB. 1979 Effects of a new glucocorticoid, oxazacort, on some variables connected with bone metabolism in man: a comparison with prednisone. Int J Clin Pharmacol Res. 5:126–134.
  8. Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV. 1984 Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int. 36:245–252.[CrossRef][Medline]
  9. Gray R, Harrington C, Coulton L, Galloway J, de Broe M, Kanis J. 1990 Long-term treatment of chronic inflammatory disorders with deflazacort. J Orthop Rheumatol. 3:15–27.
  10. Gennari C, Imbimbo B. 1985 Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int. 37:592–593.[Medline]
  11. Lo Cascio V, Bonucci E, Imbimbo B, et al. 1984 Bone loss after glucocorticoid therapy. Calcif Tissue Int. 36:435–438.[CrossRef][Medline]
  12. Pagano GF, Bruno A, Cavallo-Perin P, Cesco L, Imbimbo B. 1989 Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Arch intern Med. 149:1093–1101.
  13. Arizon JM, Anguita M, Vallés F, et al. 1993 Preliminary experience with deflazacort, a new synthetic steroid with fewer undesirable side effects, in heart transplant patients. J Heart Lung Transplant. 12:445–449.[Medline]
  14. Heymsfield SB, Wang J, Lichtman S, et al. 1989 Body composition in elderly subjects: a critical appraisal of clinical methodology. Am J Clin Nutr. 50:1167–1175.
  15. Mazess RB, Barden HS, Bisek JP, Hanson J. 1990 Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 51:1106–1112.[Abstract/Free Full Text]
  16. Avioli LV. 1993 Potency ratio–a brief synopsis. Br J Rheumatol. 32(Suppl 2):24–26.
  17. Loftus J, Allen R, Hesp R, et al. 1991Randomized, double blind trial of deflazacort vs. prednisone in juvenile chronic or rheumatoid arthritis: a relatively bone sparing effect of deflazacort. Pediatrics. 88:428–436.
  18. Piccoli A, Gastaldon F, Pillon L, et al. 1993 Bioequivalence of deflazacort and prednisone in the treatment of idiopathic nephrotic syndrome, a pilot study. Curr Therapeutic Res. 54:588–597.[CrossRef]
  19. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. 1991 Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab. 72:367–373.[Abstract]
  20. Scudeletti M, Pende D, Barabino A, et al. 1984 Effect of single oral doses of prednisone and deflazacort on human lymphocyte distribution and functions. Analysis with monoclonal antibodies. Adv Exp Med Biol. 171:335–344.[Medline]
  21. Belker ME, Massey DM, Vaughan L, et al. 1993 Comparative clinical efficacy of deflazacort and prednisone in the treatment of steroid-dependent asthma and asthmatic bronchitis (a multicenter study). Kansas City, KS: Clinical Research and Statistics Department, Marion Merrel Dow.
  22. Krogsgaard MR, Lund B, Johnsson B. 1995 A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol. 22:166–1662.
  23. Elli A, Rivolta R, Di Palo FQ, Parenti M, Vergallo G, Palazzi P, Zafiropulu S, Abelli P, Zanussi C. 1993 A randomized trial of deflazacort vs. 6-methylprednisolone in renal transplantation–immunosuppressive activity and side effects. Transplantation. 55:209–212.[Medline]
  24. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles D. 1991 Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 325:544–550.[Abstract]
  25. Melton JL, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL. 1993 Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 8:1227–1233.[Medline]
  26. Olgaard K, Storm T, Wowern NV, et al. 1992 Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone vs. deflazacort. Calcif Tissue Int. 50:490–497.[CrossRef][Medline]
  27. Devogelaer JP, Huaux JP, Dufour JP, et al. 1987 Bone sparing action of deflazacort vs. equivalent doses of prednisone: a double blind study in males with rheumatoid arthritis. In: Christiansen C, Johansen JC, Riis BJ, eds. Osteoporosis. Copenhagen: Osteopress; vol 2:1014–1015.
  28. Gennari C, Imbimbo B. 1985 Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int. 37:592–593.
  29. Montecucco C, Baldi F, Fortina A, et al. 1988 Serum osteocalcin (bone Gla protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort. Clin Rheumatol. 7:366–337.[CrossRef][Medline]
  30. Rambausek M, Ritz E, Pomer S, Mohring K, Rohl L. 1988 Alkaline phosphatase levels in renal transplant recipients receiving cyclosporine or azathioprin/steroids. Lancet. 1:247.
  31. Gennari C. 1993 Differential effect of glucocorticoids on calcium absorption and bone mass. Br J Rheumatol. 32:11–14.
  32. Arizón JM, Anguita M, Vallés F, et al. 1993 A randomized study comparing deflazacort and prednisone in heart transplant patients. J Heart Lung Transplant. 12:864–868.[Medline]
  33. Horber FF, Thomi F, Casez JP, Fonteille J, Jaeger Ph. 1992 Impact of hydration status on body composition as measured by dual x-ray absorptiometry (DXA) in normal volunteers and patients on hemodialysis. Br J Radiol. 65:895–900.[Abstract]



This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
G. Saviola, L. Abdi. Ali, S. Shams. Eddin, A. Coppini, F. Cavalieri, L. Campostrini, S. Sacco, M. Bucci, G. Cirino, and M. Rossini
Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study
Rheumatology, June 1, 2007; 46(6): 994 - 998.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
B. J Foster, J. Shults, B. S Zemel, and M. B Leonard
Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids
Am. J. Clinical Nutrition, November 1, 2004; 80(5): 1334 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Carpentier, B. W. Patterson, K. D. Uffelman, A. Giacca, M. Vranic, M. S. Cattral, and G. F. Lewis
The Effect of Systemic Versus Portal Insulin Delivery in Pancreas Transplantation on Insulin Action and VLDL Metabolism
Diabetes, June 1, 2001; 50(6): 1402 - 1413.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lippuner, K.
Right arrow Articles by Jaeger, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lippuner, K.
Right arrow Articles by Jaeger, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals